Dynamics of Antibiotic Resistant *Mycobacterium tuberculosis* during Long-Term Infection and Antibiotic Treatment

Solomon H. Mariam\(^1,2\), Jim Werngren\(^1\), Joakim Aronsson\(^3\), Sven Hoffner\(^1\), Dan I. Andersson\(^3,4\)

\(^1\) Swedish Institute for Infectious Disease Control, Solna, Sweden, \(^2\) Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia, \(^3\) Department of Infectious Diseases, County Hospital Ryhov, Jönköping, Sweden, \(^4\) Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden

Abstract

For an infecting bacterium the human body provides several potential ecological niches with both internally (e.g. host immunity) and externally (e.g. antibiotic use) imposed growth restrictions that are expected to drive adaptive evolution in the bacterium, including the development of antibiotic resistance. To determine the extent and pattern of heterogeneity generated in a bacterial population during long-term antibiotic treatment, we examined in a monoclonal *Mycobacterium tuberculosis* infection antibiotic resistant mutants isolated from one patient during a 9-years period. There was a progressive accumulation of resistance mutations in the infecting clone. Furthermore, apparent clonal sweeps as well as co-existence of different resistant mutants were observed during this time, demonstrating that during treatment there is a high degree of dynamics in the bacterial population. These findings have important implications for diagnostics and treatment of drug resistant tuberculosis infections.

Introduction

In 2009, tuberculosis disease (TB) due to *Mycobacterium tuberculosis* infections caused an estimated 1.3 million deaths globally [1]. When active TB is manifested the infection is normally treated with antibiotics, thereby providing an external pressure for the selection of antibiotic resistant bacilli. The risk of resistance development will be determined by a number of different factors, including the antibiotic selective pressure (set by the number, dosing and quality of the used drugs), any pre-existing resistances in the infecting clone, the immune status of the treated individuals and their compliance with the drug regime [2–4]. In addition, since all resistance development in *M. tuberculosis* occurs via mutational changes in the chromosome, the bacterial population size and the bacterial mutation rate will also affect the probability by which resistant clones appear de novo during treatment [5]. Furthermore, the ability of a resistant clone to grow and rise in frequency in the treated individual is influenced by the effect of the resistance on bacterial fitness [6,7].

The primary drugs used in treatment of *M. tuberculosis* infections are isoniazid and rifampicin and resistance to these drugs may be caused by mutations in a number of genes, including *inhA*, *katG*, and *rpoB*, [isoniazid] and *rpoB* (rifampicin) [8–11]. Other primary drugs used include ethambutol, pyrazinamide and streptomycin where mutations in the *emB* (ethambutol), *pncA* (pyrazinamide) and *rpsL*/*rrs* (streptomycin) genes confer resistance [12–14]. In addition, there are several second-line antibiotics available but many of them are less efficacious, give more side-effects and are more expensive than the first-line drugs. Examples of second-line drugs include aminoglycosides, polypeptides, fluoroquinolones, thiostrepton, thiacetazone and p-aminosalicylic acid [15].

The effects of resistance to rifampicin, isoniazid and streptomycin on fitness have been examined in *M. tuberculosis* and other bacterial species, and depending on which gene is mutated and the particular mutation the effect might range from no effect to a severe reduction in fitness. For example, most mutations in *rpsL* seem to reduce fitness [16–19]. In contrast, the fitness effects of mutations in the *rpsL* and *katG* genes vary greatly depending on the specific mutation. Thus, the *katG* mutants Ser315→Thr and *rpsL* mutation Lys42→Arg have no or small effects on fitness, while the Thr275→Pro (*katG*) and Lys442→Thr and Lys442→Asn (*rpsL*) mutations significantly reduce fitness [20–26]. As expected, the frequencies by which these different mutants are recovered clinically from patients correlate with their fitness measured in vitro [17,24–26]. These findings demonstrate that fitness is a major determinant of the ability of these different resistant mutants to spread and establish infections [7,25].

Even though several studies of the long-term dynamics of drug resistance in rapidly mutating viruses with large populations have been performed [27,28], less is known about resistance dynamics in bacteria. Partly this is because the lower mutation rates in bacteria, and the resulting lower rates by which drug resistant variants appear, imply that there is less dynamics in the population. However, some studies of bacterial diversity in, for example, *Pseudomonas aeruginosa* [29,30] and *Helicobacter pylori* [31,32] suggest that also in bacterial infections population...
heterogeneity might be considerable, especially during long-term or chronic infections.

To address the extent of heterogeneity and dynamics in antibiotic resistant variants during a monoclonal infection in a host, we examined serial M. tuberculosis Beijing isolates obtained from one patient during a 9-year period of infection and disease where the successive accumulation of resistance mutations ultimately made the infection untreatable and caused death of the patient. Her isolates belonged to the W-Beijing family of M. tuberculosis, which are especially prevalent in East Asia and Eastern Europe [33–35], and are genetically identified by their characteristic IS6110 and spoligotypes patterns and katG463and gyrA95 mutations [35]. Moreover, we examined the heterogeneity and dynamics with respect to aminoglycoside resistance within 10 single colony isolates (sub-clones) derived from each of the original serial patient isolates. Analysis of these sub-clones showed that there is a high degree of dynamics in the infecting bacterial population, including successive changes in antibiotic resistance types and bacterial fitness. These findings have important implications for treatment and diagnostics of antibiotic resistance in infected individuals.

**Materials and Methods**

**Isolates**

The isolates that were characterized were clinical isolates obtained from the same patient during a period of 9 years (1991–1999). These isolates were kept frozen at −70°C in Middlebrook 7H9 broth containing 10% glycerol. A fresh aliquot was taken for analysis and prior to all experiments, the isolates were cultured on Lowenstein-Jensen slants for 3 to 4 weeks at 37°C. The isolates and the time of isolation together with their drug resistance patterns are listed in Table 1.

**Drug Susceptibility Testing of Serial Isolates**

Drug susceptibility testing of the isolates to the various drugs (isoniazid, rifampicin, streptomycin, ethambutol, amikacin) were performed using the BACTEC 460TB system according to the instructions of the manufacturer.

**DNA Extraction**

For DNA extraction, the isolates were first grown on Lowenstein-Jensen (LJ) medium. Bacterial cells were then transferred into 1.5 ml micro-centrifuge tubes containing 250 μl of 1× TE buffer using a sterile loop followed by killing by heating at 80°C for 1 hr. Cells were then centrifuged at 13,000 rpm for 2 min. The supernatant was discarded and the pellet resuspended in 500 μl of 150 mM NaCl, followed by centrifugation. This was repeated once. Finally, the DNA pellet was resuspended in 25 μl of TE buffer.

**Amplification of DNA by PCR and Sequencing**

PCR reactions were carried out in a 50 μl volume containing 0.5 μM of each primer, 200 μM of each dNTP, 5 μl of 10× PCR buffer, 0.25 μl of AmpliTaq Gold DNA polymerase, 1 μl of DNA and 2 mM MgCl₂ except for the primer pair used to amplify the 1400 region of rrs, for which the MgCl₂ concentration was 3 mM. The primers, size of fragments targeted for amplification and cycling conditions are listed in Table S1. The GeneAmp® PCR System 9700 was used for running PCR and sequencing reactions. PCR products were purified using GFXTM PCR and Gel Band Purification Kit (Amersham Pharmacia Biotech). The same primers as used for PCR were used in cycle sequencing reactions. The sequenced genes were katG, embB, rpoB, rpsL, and rrs.

**Table 1. Date of isolation and resistance pattern of the different isolates of M. tuberculosis as tested in the BACTEC 460 system and antibiotic resistance mutations identified in isolates obtained from eight different time points.**

| Patient isolate/de isolated(D)/M/Y | Isolate No. | Drug/target gene sequenced | Rifampicin/gzd | Streptomycin/rrs | Ethambutol/embB | Amikacin/95 | S/R a Mutation | S/R a Mutation | S/R a Mutation | S/R a Mutation | S/R a Mutation |
|----------------------------------|-------------|---------------------------|--------------|----------------|----------------|-------------|---------------|---------------|---------------|---------------|---------------|
| 1/2-4-91/S91-222                 |             |                           | R            | AGC            | GAC            | R           | S             | R             | S             | R             | S             |
| 2/12-7-91/S91-224                |             |                           | R            | AGC            | GAC            | R           | GAC           | S             | GAC           | R             | GAC           |
| 3/11-9-91/S91-263                |             |                           | R            | AGC            | GAC            | R           | GAC           | R             | GAC           | R             | GAC           |
| 4/13-12-91/S92-001               |             |                           | R            | AGC            | GAC            | R           | R             | S             | A513C         | R             | S             |
| 5/5-2-92/S92-031                 |             |                           | R            | AGC            | GAC            | R           | AAG           | S             | R             | S             | A513C         |
| 6/14-12-92/S93-007               |             |                           | R            | AGC            | GAC            | R           | AAG           | R             | R             | S             | A513C         |
| 7/5-2-93/S93-021                 |             |                           | R            | AGC            | GAC            | R           | AAG           | R             | S             | A513C         | A1400G        |
| 8/N-3-99/S99-293                 |             |                           | R            | AGC            | GAC            | R           | AAG           | R             | S             | A513C         | A1400G        |

**Abbreviations:** S = Susceptible, R = Resistant.

a: Streptomycin-resistant isolates with wild-type gyrA were checked for mutation in rrs. The A513C mutation in rrs confers streptomycin resistance whereas the A1400G mutation confers amikacin resistance.
Sequencing was performed using both forward and reverse primers. Sequencing reactions were run with an initial denaturation at 96°C for 1 min followed by 25 cycles each at 96°C for 10 sec, 50°C for 5 sec and 60°C for 4 min. Sequences were obtained using ABI PRISM 3100 Genetic Analyzer. Mutations were identified by importing sequencing products into the BLAST2 nucleotide sequence alignment tool.

Analysis of aminoglycoside resistance mutation spectra in sub-clones

Because initial sequencing of the gene [@(psbL and rps) segments in which mutations occur to cause streptomycin and amikacin resistance in the successive serial isolates revealed changing patterns (wild-type to mutant and back to wild-type again), each of the 8 isolates were first grown on duplicate plates on Middlebrook 7H10 medium containing 10% OADC enrichment (M7H10 medium) to obtain single colonies. Then, 10 single colonies (sub-clones) were randomly picked from two different plates on day 16 of culture and grown in Middlebrook 7H9 medium containing 10% ADC enrichment and 0.1% Tween 80 (M7H9 medium) for 3 weeks followed by inoculation onto LJ medium. DNA extraction, PCR amplification and sequencing were performed as described above for the isolates to identify the spectrum of mutations.

Molecular Typing of Serial Isolates

The serial isolates were typed by both spoligotyping [36] and restriction fragment length polymorphism (RFLP) [37]. The similarities of the RFLP patterns were determined by using BioNumerics version 3.0 software (Applied Maths, Sint Maarten Later, Belgium). Results are shown in Figure S1.

Determination of relative fitness by competition experiments

To determine the relative fitness of the various isolates, head-to-head competitions were performed in liquid cultures. Isolate 1.1 (isolated on 2/4/91 from the patient) was arbitrarily chosen as the parent and all competitions were then performed between this parental isolate and sub-clones from subsequent isolates. Since the parent isolate was susceptible to rifampicin and all the subsequent isolates were highly resistant, rifampicin was used to distinguish the parent and competitors. The parental isolate and the competitor suspensions were mixed in 20 ml of 7H9 medium. Since we expected that the mutants would be outcompeted, competition experiments were started with mutants in slight excess (3:1) to the competitor outcompeted the parent and <1 the opposite. Fourteen days of incubation correspond to approximately 15–20 generations of growth for the parental strain. The data presented represent the averages of two independent experiments for each of the mutant types. Control experiments showed that the plating efficiency of the resistant mutants was unaffected by the presence of rifampicin.

Ethics Statement

This in vitro study was carried out on a number of clinical isolates of *M. tuberculosis* obtained from one patient with multi-drug-resistant tuberculosis. The isolates were collected during the period 1991 to 1999 and kept at the strain collection of the Swedish Institute for Infectious Disease Control. The patient died in 2000, four years before the study was initiated, and the results obtained did not in any way affect the clinical treatment or outcome, i.e. the samples were taken as part of routine clinical care and specific consent was therefore not needed and acquired. Exemption from ethical approval was provided by the institutional review board at the Karolinska Institute (Regional Ethical Review Board in Stockholm, FE 289 171 77 Stockholm) who stated that this in vitro study on clinical isolates and their drug resistance carried out at our laboratory is excluded from the demand of a specific ethical permission.

Results

Patient data, antibiotic prescription and antibiotic resistance from 1991–1999

At the time of diagnosis of lung tuberculosis, March 1991, the Swedish female patient was 19 years old and she was then intermittently antibiotic treated until she died of tuberculosis in July 2000. The treatment and resistance pattern is shown in Table 2 and indicates the types of antibiotic used during the period 1991–2000 and the resistance pattern of the bacteria. Standard drug susceptibility testing [using the BACTEC 460TB system of the serially obtained bacterial samples showed that the isolates exhibited resistance to an increasing number of drugs (Table 1). The first isolate was resistant to isoniazid only. The second isolate also acquired resistance to rifampicin. The third through seventh isolates were resistant to isoniazid, rifampicin and streptomycin and this triple resistance developed within about six months (Table 1). The eighth isolate was resistant to all these drugs and to the second-line drug amikacin.

**IS6110 based RFLP and spoligotyping indicates the presence of one clone during infection**

The IS6110 RFLP patterns of the bacterial isolates isolated from 1991 to 1999 were identical as shown in Fig. S1. In addition, the spoligotyping pattern showed that they had the 9-band hybridisation to spacers 35–43 characteristic of Beijing isolates (Fig. S1). These data strongly suggest that the patient carried the same single clonal type during 9 years of infection and that no re-infection with other strains occurred during this period.

Heterogeneity of resistance mutations between different time points

The respective gene fragments of these eight isolates were subjected to PCR and DNA sequencing to detect the presence of potential mutations in the *katG*, *rpoB*, *psbL*, *embB* and *rps* genes. Initial sequencing revealed that all eight isolates carried the AGC315→ACC mutation responsible for isoniazid resistance and an additional CGG463→CTG mutation in *katG*.
| Date     | Apr91 | May91 | May91 | Jul91 | Aug91 | Oct91 | Oct91 | Nov91 | Dec91 | Dec91 | Apr92 | Oct92 | Sep92 | Oct93 | Nov93 | Dec93 | Mar94 | Jul94 | Jul94 | Sep94 | Oct94 | Nov94 | Dec94 | Jan95 | Feb95 | Mar95 | Apr95 | May95 | Jun95 | Jul95 | Aug95 | Sep95 | Oct95 | Nov96 | Dec96 | Jan97 | Feb97 | Mar97 | Apr97 | May97 | Jun97 | Jul97 | Aug97 | Sep97 | Oct97 | Nov98 | Dec98 | Jan99 | Feb99 | Mar99 | Apr99 | May99 | Jun99 | Jul99 | Aug99 | Sep99 | Oct99 | Nov00 |
|----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|------- |
| **Antibiotics** |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Azithromycin     |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Amikacin         |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Capreomycin      |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Ciprofloxacin    |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Clarithromycin   |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Clofazimin       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Cycloserine      |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Ethambutol       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Ethionamide      |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Isoniazid        |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Levofloxacin     |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| PABA             |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Protionamide     |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Pyrazinamide     |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Rifabutin        |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Rifampcin        |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Streptomycin     |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Thioacetazone    |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |

An X indicates that the patient was treated with that antibiotic. R, I and S refer to resistant, intermediate and susceptible. The patient was not treated during the period 13 Nov 1996 to 8 Apr 1999.
and sequencing of the rpsL gene (note that the initial testing of drug susceptibility resistance mutations within the bacterial population isolated from that there might be heterogeneity with regard to the streptomycin heterogeneity within each population, the rpsL gene had not been single-cell colony purified). To assess the potential genetic bacterial populations obtained from each time point and that had been shown to be responsible for amikacin resistance in both clinical and in vitro isolates of M. chelonae, M. abscessus and M. tuberculosis [42,43].

**Dynamics of streptomycin resistance mutations within and between sub-clones**

The initial sequencing of all isolates showed the presence of one or the other of at least three different mutations in rpsL or rrs. These were the AAG87→AGG and AAG42→AGG mutations in rpsL, and A513→C in rrs in isolates 3–8. These data thus suggested that there might be heterogeneity with regard to the streptomycin resistance mutations within the bacterial population isolated from each time point (note that the initial testing of drug susceptibility and sequencing of the rpsL and rrs genes were performed on bacterial populations obtained from each time point and that had not been single-cell colony purified). To assess the potential genetic heterogeneity within each population, the rpsL and rrs gene segments responsible for streptomycin resistance were sequenced from 10 randomly selected sub-clones obtained from the eight time points (Table 3).

From both the susceptibility data and sequencing of the rpsL gene, sub-clones of isolates 1 and 2 were shown to be sensitive to streptomycin and wild-type in rpsL (Tables 1 and 4). Most sub-clones of subsequent isolates 3, 4 and 5 harbored the AAG87→AGG streptomycin resistance mutation, with only two sub-clones harboring the AAG42AGG mutation in rpsL (sub-clones 3.8 and 4.3) or A513C mutation in rrs (sub-clone 3.2) (Table 3). (The A513→C mutation alone in rrs is known to confer streptomycin resistance in E. coli [44] and clinical isolates of M. tuberculosis [14]). Thus, the heterogeneity was evident within and between the sub-clones (e.g., 3.2 and 3.8, which are different from each other and the other sub-clones of isolate 3 as well as from the sub-clones of isolate 5, Table 3). A sub-clone of isolate 5 (5.5) yielded ambiguous sequencing result in rpsL (AGG87→ANG. One sub-clone (5.10) was found to be wild-type for both rpsL and rrs.

With regard to the streptomycin resistance mutations, at least four different types (rpsL87AGG, rrsA513C, rpsL42AGG and rpsL42AGG + rrsA1400G) were identified during the sampling period. This is likely to be an underestimate since we only examined 10 independent sub-clones for each time point and during the period 1993–1999 sampling was sparse. A shift in the bacterial population from AAG87→AGG to the AAG42→AGG variant is seen from isolate 6 onwards (except for isolate 7 most sub-clones of which carried the A513→C mutation in rrs, with only two of its sub-clones [7.1 and 7.7] carrying the AA-42→AGG mutation).

**Fitness and frequencies of different streptomycin resistant types**

To determine the competitive fitness of the different streptomycin resistant mutants isolated during the course of the infection, we performed *in vitro* competition experiments where the different streptomycin resistant sub-clones were competed against a sub-clone obtained from the first isolate obtained in 1991 (resistant to isoniazid and susceptible to rifampicin, ethambutol, streptomycin and amikacin, see 1 [S91-222 [1, parent]] in Table 4. *In vitro* competitions in rich culture medium have been shown in previous

---

**Table 3. Heterogeneity in types of streptomycin resistance mutations isolated during treatment.**

| Parent isolate | Sub-clones | Gene | rpsL (numbers indicate amino acid position) | rrs mutation | Nucleotide A513 | Nucleotide A1400 |
|----------------|------------|------|------------------------------------------|--------------|----------------|----------------|
| 1 (S 91-222)   | 1.1–1.10   | wt   | AAG87→AGG                                | C            | wt             | wt             |
| 2 (S 91-224)   | 2.1–2.10   | wt   | AAG87→AGG                                | C            | wt             | wt             |
| 3 (S 91-263)   | 3.1–3.3   | AAG42→AGG | AAG87→AGG                                | C            | wt             | wt             |
| 3 (S 91-263)   | 3.2        | wt   | A513→C                                   | C            | wt             | wt             |
| 3 (S 91-263)   | 3.8        | AAG42→AGG | AAG87→AGG                                | C            | wt             | wt             |
| 4 (S 92-001)   | 4.1–4.10   | AAG87→AGG | AAG87→AGG                                | C            | wt             | wt             |
| 4 (S 92-001)   | 4.3        | AAG42→AGG | AAG87→AGG                                | C            | wt             | wt             |
| 5 (S 92-031)   | 5.1–5.9    | AAG87→AGG | AAG87→AGG                                | C            | wt             | wt             |
| 5 (S 92-031)   | 5.5        | AAG87→ANG | AAG87→AGG                                | C            | wt             | wt             |
| 5 (S 92-031)   | 5.7        | ND   | AAG87→AGG                                | C            | wt             | wt             |
| 6 (S 93-007)   | 6.1–6.10   | AAG42→AGG | AAG87→AGG                                | C            | wt             | wt             |
| 7 (S 93-021)   | 7.1–7.7    | AAG42→AGG | AAG87→AGG                                | C            | wt             | wt             |
| 7 (S 93-021)   | 7.2–7.10   | AAG42→AGG | AAG87→AGG                                | C            | wt             | wt             |
| 8 (S 99-293)   | 8.1–8.10   | AAG42→AGG | AAG87→AGG                                | C            | wt             | wt             |
| 8 (S 99-293)   | 8.8        | wt   | AAG87→AGG                                | C            | wt             | wt             |

| doi:10.1371/journal.pone.0021147.t003 |
Discussion

The presented results show that there is extensive dynamics in the bacterial population during a long-term *M. tuberculosis* infection. As expected, over time and with cumulative antibiotic exposure there was a progressive accumulation of resistances in the infecting clone. More unexpected was the dynamics observed for the streptomycin resistant sub-clones, where successive clonal sweeps as well as transient co-existence of different streptomycin-resistant variants were observed during the 9-year period (Table 3). During growth in the patient fitness of the antibiotic resistant sub-clones changed (Table 4), suggesting that they adapted to the fitness costs associated with the resistance mutations. Thus, in several cases fitness appeared to increase over time but in other cases fitness was reduced, suggesting that the within host dynamics is complex and that the growth rate measured in vitro is not necessarily a direct predictor of bacterial growth and survival within a patient.

It is commonly assumed in bacterial infections that one resistance type (primary or acquired) goes to fixation in the population in response to an imposed antibiotic pressure. Instead of such fixation, we observed successions as well as co-existence of resistant mutants (Table 3). These results are of relevance both from an evolutionary point of view as well as for diagnostics and treatment of TB. As seen from previous *in vitro* fitness assays, several of the common resistance mutations (e.g. *rplB*7AGG and *rpsL*4513C) found in clinical isolates of *M. tuberculosis* cause a reduction in fitness [24–26,45]. These mutations were also found in isolates from this patient. In some certain cases, these resistant mutants either disappeared or were replaced by other more fit mutants (e.g. *rpsL*87AGG was replaced by *rpsL*42AGG from 1992 to 1993) or their fitness was increased due to other unknown mutations (e.g. subclones 3.1 and 4.4 versus 5, and subclones 3.2 versus 7.2) [19,45,50]. Thus, it is possible that more fit multi-resistant mutants may be selected during treatment and subsequently spread to other individuals [6,25]. Interestingly, the succession of streptomycin resistant *rpsL* mutants (i.e. *rpsL*87AGG was replaced by *rpsL*42AGG) observed in our isolates is reminiscent of that seen in a previous study where serial isolates from a single patient showed a similar succession of *rpsL* mutant types [46]. Furthermore, heterogeneity in resistance types can involve other drugs than streptomycin, as shown for ethambutol and fluoroquinolones where parallel evolution in distinct lung compartments from a single founder strain was suggested to generate heterogeneity in resistance-associated alleles for isolates with identical IS6110 RFLP pattern [47].

It has been shown that heterogeneity exists in the resistant bacterial populations within the host [46,47] and it is conceivable that the frequencies with which different drug resistant mutants are isolated in patients partly is determined by their differences in fitness. Support for this notion comes from the observation that a positive correlation between the frequency of isolation of resistant mutants and their relative fitness (e.g., *Ser*351→*Leu* in *rpoB* (rifampicin resistance), *Lys*42→*Arg* in *rpsL* (streptomycin resistance), *Ser*315→*Thr* in *katG* (isoniazid resistance) has been reported for *M. tuberculosis* [5,17,19,23–26]. There is ample support for compensatory evolution of fitness costs associated with resistance mutations [16,20–21,45–52], and it is conceivable that such evolution also influences the fitness of the resistant mutants studied in this and other work. Thus, the differences in fitness observed between sub-clones with the same resistance mutations might indicate compensatory evolution. However, we cannot exclude the possibility that the observed fitness differences are caused by other fitness-altering genetic changes, unrelated to the resistance mutations.

Finally, our findings are relevant from the point of view of resistance diagnostics. Thus, most current clinical and research procedures to determine resistance patterns are based on examination of single isolates from a given disease episode with the assumption that this isolate is representative of a homogenous bacterial population. Recent studies have shown that this assumption is invalid and demonstrated the occurrence of both mixed clonal infections as well as exogenous re-infection where a patient is re-infected by a second clone during a recurrent episode [53,54]. This study demonstrates that within a specific clone there is also extensive heterogeneity with respect to the resistant mutants selected and maintained over time. Since fitness and resistance levels might vary between resistant types it is important to know the population composition at different time points to assure that the proper drug combinations are used. To obtain a measure of this heterogeneity several independent bacterial clones needs to be examined from each patient sample. Furthermore, the heterogeneity in resistance mutations observed here is most likely an underestimate since we only examined streptomycin resistance, sampling was sparse during some time intervals (i.e. 1993–1999), and only ten sub-clones were studied from each sampling.

**Supporting Information**

**Figure S1** Spoligotyping and RFLP pattern of serial clinical isolates of *M. tuberculosis*. S99-293 = isolate 8, S91-222 = isolate 1,
S91-224 = isolate 2, S91-263 = isolate 3, S92-001 = isolate 4, S92-031 = isolate 5, S93-007 = isolate 6, S93-021 = isolate 7.

(DOCX)

Table S1 Primers and PCR conditions for amplification of resistance genes.

(DOCX)

References

1. World Health Organization (2009) WHO Report 2009. Global tuberculosis control, surveillance, planning, financing. A Short Update to the 2009 Report.
2. Austin EJ, Kristinsson KG, Anderson RM (1999) The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci U S A 96: 1152-1156.
3. Lipsitch M, Samore MH (2002) Antimicrobial use and antimicrobial resistance: a population perspective. Emerg Infect Dis 8: 347-354.
4. Handel A, Margolis E, Levin BR (2008) Exploring the role of the immune response in preventing antibiotic resistance. J Theor Biol 256: 655-662.
5. Gillespie SH (2002) Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother 46: 267-274.
6. Cohen T, Murray M (2004) Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med 10: 1117-1121.
7. Andersson DI, Hughes D (2010) Antibiotic resistance and its costs: is it possible to reverse resistance? Nat Rev Microbiol 8: 269-271.
8. Zhang Y, Heym B, Allen B, Young D, Cole ST (1992) The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358: 591-595.
9. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, et al. (1994) inA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263: 237-240.
10. Václavík C, Weibrod TR, Chen B, Kremer L, Hasson MH, et al. (2005) Altered NADH/NAD+ ratio mediates co-resistance to isoniazid and rifampin in mycobacteria. Antimicrob Agents Chemother 49: 708-720.
11. Tzeng Y, Izbudak P, Marchesi F, Leowie D, Cole S, et al. (1993) Detection of rifampin-resistance mutations in Mycobacterium tuberculosis. Lancet 341: 647-650.
12. Tzeng Y, Philip WJ, Sreevatsan S, Bernasconi C, Stockbauer KE, et al. (1997) The sub-species and strain of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med 3: 567-570.
13. Scorpio A, Zhang Y (1996) Mutations in parC, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antitubercular drug pyrazinamide in tubercle bacilli. Nat Med 2: 662-667.
14. Finken M, Kirschen P, Meier A, Weide A, Botter EC (1993) Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S rRNA pseudoknot. Mol Microbiol 9: 1239-1246.
15. Caminero JA, Sotgiu G, Zumla A, Migliori GB (2010) Best drug treatment for multidrug-resistant tuberculosis. Curr Opin Pulm Med 16: 647-650.
16. Reynolds MG (2000) Compensatory evolution in rifampin-resistant Mycobacterium tuberculosis. Science 288: 1152-1156.
17. Billington OJ, McHugh TD, Gillepie SH (1999) Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 43: 1086-1089.
18. Marais DH, Mengstu Y, Hofflin SH, Anderson DI (2004) Effect of spdB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob Agents Chemother 48: 1289-1294.
19. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, et al. (2006) The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 314: 1942-1946.
20. Björkman J, Hughes D, Anderson DI (1998) Virulence of antibiotic-resistant Salmonella typhimurium. Proc Natl Acad Sci U S A 95: 3949-3953.
21. Björkman J, Nagae I, Berg OG, Hughes D, Anderson DI (2000) Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287: 1479-1482.
22. vanSoolingen D, de Haas PL, van Doorn HR, Kuijper E, Rinder H, et al. (2000) Directed mutagenesis of EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother 44: 325-326.
23. vanDooren HR, Kuiper EJ, van derEinde A, Welsa AG, van Soolingen D, et al. (2001) The susceptibility of Mycobacterium tuberculosis to isoniazid and the Arg→Leu mutation at codon 463 of katG are not associated. J Clin Microbiol 39: 1591-1594.
24. Ramaswamy SV, Amin AG, Gokel S, Steg CE, Dou S-J, et al. (2000) Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 44: 326-336.
25. Goude R, Amin AG, Chatterjee D, Parish T (2009) The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother 53: 4138-4140.
26. vanSoolingen D, Sander P, Brown BA, Frischkorn K, Onyi GO, et al. (1998) A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J Infect Dis 177: 1530-1531.
27. Melancon P, Lemieux C, Braker-Jeongras L (1988) A mutation in the 530 loop of Escherichia coli 16S ribosomal RNA causes resistance to streptomycin. Nucl Acids Res 16: 9631-9639.
28. Scherbakov D, Akbergoren R, Matt T, Sander P, Anderson DI, et al. (2010) Directed mutagenesis of Mycobacterium aurumgense 16S rRNA to reconstruct the in vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol Microbiol 77: 830-840.
29. Meacci F, Orru G, Iona E, Giannoni F, Piersimoni C, et al. (2005) Drug resistance evolution of a Mycobacterium tuberculosis strain from a noncompliant patient. J Clin Microbiol 43: 3114-3120.
30. Kaplan G, Post FA, Moreira AL, Wainwright H, Kreiswirth BN, et al. (2003) Mycobacterium tuberculosis: growth at the cavity surface: a microenvironment with failed immunity. Infect Immun 71: 7099-7108.

Acknowledgments

We thank Solomon Ghebremichael and Ramona Groenheit for assistance with generating the RFLP and spoligotyping data, and Linnus Sandgren and Joakim Nasvall for comments on the manuscript.

Author Contributions

Conceived and designed the experiments: SHM SH DIA. Performed the experiments: SHM JW. Analyzed the data: SHM JW SH DIA. Contributed reagents/materials/analysis tools: JA. Wrote the paper: SHM SH DIA.
48. Nagaev I, Björkman J, Anderson DI, Hughes D (2001) Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol Microbiol 40: 433–439.

49. Maisnier-Patin S, Berg OG, Liljas L, Andersson DI (2002) Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella typhimurium. Mol Microbiol 46: 355–366.

50. Sherman DR, Mdluli K, Hickey MJ, Arian TM, Morris SL, et al. (1996) Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 272: 1641–1643.

51. Björkholm B, Sjölund M, Falk PG, Berg OG, Engstrand L, et al. (2001) Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Proc NatlAcadSci U S A 98: 14607–14612.

52. Hurdle JG, O'Neill AJ, Ingham E, Fishwick C, Chopra I (2004) Analysis of mupirocin resistance and fitness in Staphylococcus aureus by molecular genetic and structural modeling techniques. Antimicrob Agents Chemother 48: 4366–4376.

53. vanRie A, Victor TC, Richardson M, Johnson R, van derSpuy GD, et al. (2005) Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. Am J Respir Crit Care Med 172: 636–642.

54. Shamputa IC, Jugeli L, Sadradze N, Willery E, Portaels F, et al. (2006) Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia. Respir Res 7: 99–109.